Posts tagged as: stock chart back to homepage

Mustang Alliances Stock Chart Analysis Video(0)

Mustang Alliances (OTCBB:MSTG) has been in a strong uptrend for several months. After a consolidation, the price per share has held the 50dma and is back on the climb looking to challenge the old highs at $1.48. Read More

Auri Inc Stock Chart Analysis Video(0)

Shares of Auri, Inc. (OTCBB:AURI) have consolidated mildly since a climb from 4 cents to 9 cents. The indicators are holding bullish positions which are signaling that the chart may be ready for another run at resistance and the 50 dma at $0.09 as support is being established at 6 cents. Read More

SANUWAVE Health Stock Chart Analysis Video(1)

After a steep drop from near $1.40 to touch 15 cents in a matter of days, the SANUWAVE Health (OTCQB: SNWV) chart had a nice bounce of 44% on Friday. The chart looks poised for the strong bounce to continue in early trading this week. Read More

Reginicin (RGIN) Stock Chart Video Reginicin (RGIN) Stock Chart Video(0)

The Regenicin stock chart is a low-volume play that appears to be trying to trend off the bottom. There is a solid positive divergence with the MACD and a support level at 16 cents that technical traders will be watching with resistance at 22 cents.

Regenicin, Inc. (OTCBB:RGIN ) is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Regenicin, which was founded in 2010, has assembled a world-class management team with a proven track record for developing and bringing innovative medical devices and biotechnology products to market. The company is publicly traded with headquarters in New Jersey. More information on the Company can be found at

Regenicin, Inc. (RGIN) Stock Quote and News:

Disclaimer: Neither nor its officers, directors, partners, employees or anyone involved in the publication of this website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The following news is published as information only for our readers. is a third party publisher of news and research .Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Please read and fully understand our entire disclaimer at

Zack’s Notes Keryx (KERX) Uptrend and 67% Change in 52 Week Zack’s Notes Keryx (KERX) Uptrend and 67% Change in 52 Week(0), a leader in investment research, has aptly noted the recent uptrend in the share price of Keryx Biopharmaceuticals over the last several weeks.  Zack’s “SmarTrend” analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time.

According to Zack’s commentary on April 5, 2011,

“In the past 52 weeks, shares of Keryx Biopharmaceuticals have traded between a low of $3.03 and a high of $6.67 and are now at $5.05, which is 67% above that low price.

Keryx Biopharmaceuticals is currently above its 50-day moving average of $4.19 and above its 200-day moving average of $4.38. Look for these moving averages to climb to confirm the company’s upward momentum.

In the last five trading sessions, the 50-day MA has climbed 1.72% while the 200-day MA has risen 0.28%.”

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.

Keryx Biopharmaceuticals (KERX) Stock Quote and News:

Star Bulk Carriers Corp. (SBLK) Video Stock Chart 2/14/2011 Star Bulk Carriers Corp. (SBLK) Video Stock Chart 2/14/2011(0)

The SBLK stock chart held a base last week with a low of $2.42.  Technical traders will be watching this chart as it is forming a PPO/ADX “pincher play” formation, which can be pretty reliable as a bottom play.  We are watching for the support level to hold and for the reversal to begin as the first resistance doesn’t come into play until the price per share reaches the area of $2.65.  Pretty nice risk versus reward setup with a close support level.  The base must hold because if it fails, there isn’t any strong support until $2.20.  View the video at

The Star Bulk Carriers Corp. (NASDAQ:SBLK) is a feature chart of Quality Stocks.

Please visit today!

Stay Informed

Receive the OTCS Newsletter *


* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

© 2011 Viper Enterprises, LLC. All rights reserved.